Cardiovascular toxicities associated with immune checkpoint inhibitors
10.3760/cma.j.cn112152-20200226-00133
- VernacularTitle:肿瘤免疫检查点抑制剂相关的心脏毒性
- Author:
Wenxian WANG
1
;
Zhengbo SONG
;
Yiping ZHANG
Author Information
1. 中国科学院大学附属肿瘤医院 浙江省肿瘤医院胸部肿瘤内科 中国科学院肿瘤与基础医学研究所，杭州 310011
- Keywords:
Tumor;
Immune checkpoint inhibitors;
Cardiotoxicity;
CTLA-4;
PD-1
- From:
Chinese Journal of Oncology
2020;42(7):609-613
- CountryChina
- Language:Chinese
-
Abstract:
With the continuous development of cancer treatment, the immune checkpoint inhibitors have been applied to the treatment of a variety of malignant tumors, which improved the patient′s survival time and quality of life. However, immune-related adverse reactions occur inevitably. Like chemotherapeutics and targeted drugs, immunosuppressants can also cause cardiovascular events that affect the mortality of cancer patients. With the extension of the survival time of cancer patients, it will increasingly become a key factor which affects the prognoses of these diseases. This review focuses on the cardiotoxic mechanism, clinical manifestation, and future direction of immune checkpoint inhibitors during cancer treatment.
